Skip to main content
Premium Trial:

Request an Annual Quote

Curetis, FIND Extend Antimicrobial Resistance Research Collaboration

NEW YORK – OpGen said on Thursday that its subsidiary Curetis and FIND have extended an antimicrobial resistance R&D collaboration following the completion of the feasibility phase of the original deal.

All milestones were met on time and within budgets, and the partners will now focus on the development of an AMR cartridge for use with blood culture that is targeted to low- and middle-income countries.

Specifically, the new deal covers the development of an AMR assay and a cartridge for the Unyvero A30 platform for AMR detection from commonly used blood culture bottles, development of a corresponding software plug-in, and analytical performance evaluation. The development phase is expected to last 10 months.

OpGen said that the budget for the extended contract is about $600,000 and will bring the total collaboration commitment to date to about $1.5 million.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.